NASDAQ: YSYs Biopharma Co Ltd Stock
$0.73-0.13 (-15.12%)
Updated Apr 19, 2024
YS Price
$0.73
Fair Value Price
N/A
Market Cap
$67.47M
52 Week Low
$0.35
52 Week High
$1.97
P/E
N/A
P/B
0.14x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.18
Operating Cash Flow
N/A
Beta
0.03
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
YS Overview
Summit Healthcare Acquisition Corporation is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar combinations with one or more businesses. It targets the healthcare industry, specifically in the pharmaceuticals, medtech, and diagnostics sectors. The company was incorporated in 2020 and is headquartered in Hong Kong.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how YS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
YS is good value based on its book value relative to its share price (0.14x), compared to the US Biotechnology industry average (5.74x)
P/B vs Industry Valuation
YS's short-term liabilities ($882.85M) exceed its short-term assets ($826.61M)
Short-term Liabilities Financials
YS's short-term assets ($826.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more YS due diligence checks available for Premium users.
Be the first to know about important YS news, forecast changes, insider trades & much more!
YS News
Valuation
YS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
15.81x
Market
40.51x
YS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.14x
Industry
5.74x
YS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
YS's financial health
Profit margin
Revenue
$165.0M
Net Income
-$77.8M
Profit Margin
-47.1%
Assets to liabilities
Assets
$1.5B
Liabilities
$1.0B
Debt to equity
2.18
YS's short-term liabilities ($882.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
YS's short-term assets ($826.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
YS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
YS vs Biotech Stocks
Ys Biopharma Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.